A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

被引:30
作者
Cusi, Kenneth [1 ,2 ]
机构
[1] Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL USA
[2] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
FATTY LIVER-DISEASE; TYPE-2; DIABETES-MELLITUS; PLACEBO-CONTROLLED TRIAL; PIOGLITAZONE; MANAGEMENT; LIRAGLUTIDE; SITAGLIPTIN; MECHANISMS; DIAGNOSIS;
D O I
10.1111/liv.14350
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is a close link between steatohepatitis (NASH) and Type 2 diabetes (T2DM). Recently, the American Diabetes Association (ADA) recommended screening for NASH and advanced fibrosis in patients with diabetes and hepatic steatosis or elevated plasma alanine aminotransferase (ALT). This is because as many as similar to 30% to 40% may have NASH and similar to 10% to 15% advanced fibrosis. The role of hyperglycemia and the natural history of NASH in diabetes remain poorly understood, as well as which diagnostic algorithm or interventions are most cost-effective. There is significant clinical inertia and most patients today are still not receiving adequate lifestyle intervention or pharmacological treatment with diabetes agents known to be effective against NASH. Lifestyle intervention improves steatohepatitis in proportion to the magnitude of weight loss, but this trend is not as consistent for regression of fibrosis. This limited success supports the need for concomitant pharmacological therapy. Pioglitazone has been shown to consistently induce resolution of NASH in both patients with or without diabetes in a total of 498 participants in five randomized controlled trials (RCTs), but with modest effects on liver fibrosis. Proof-of-concept studies suggest a potential role for GLP-1RAs and SGLT2 inhibitors. Combination therapy is on the horizon. Treating diabetes and NASH with a combination of pioglitazone, GLP-1RAs or SGLT2i, could be a cost-effective strategy to treat both diseases while reducing their high cardiovascular risk. Future combination therapies will likely combine existing diabetes agents with novel NASH-spechfic drugs under development. This review highlights current knowledge gaps and proposes future directions for the treatment of NASH in diabetes.
引用
收藏
页码:82 / 88
页数:7
相关论文
共 56 条
  • [1] Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
    Aithal, Guruprasad P.
    Thomas, James A.
    Kaye, Philip V.
    Lawson, Adam
    Ryder, Stephen D.
    Spendlove, Ian
    Austin, Andrew S.
    Freeman, Jan G.
    Morgan, Linda
    Weeber, Jonathan
    [J]. GASTROENTEROLOGY, 2008, 135 (04) : 1176 - 1184
  • [2] Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
    Akuta, Norio
    Kawamura, Yusuke
    Watanabe, Chizuru
    Nishimura, Akihiro
    Okubo, Minoru
    Mori, Yasumichi
    Fujiyama, Shunichiro
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. HEPATOLOGY RESEARCH, 2019, 49 (05) : 531 - 539
  • [3] [Anonymous], 2000, Endotext [Internet]
  • [4] [Anonymous], DIABETES CARE
  • [5] [Anonymous], DIABETES CARE
  • [6] [Anonymous], J HEPATOL
  • [7] Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
    Anstee, Quentin M.
    Lawitz, Eric J.
    Alkhouri, Naim
    Wong, Vincent Wai-Sun
    Romero-Gomez, Manuel
    Okanoue, Takeshi
    Trauner, Michael
    Kersey, Kathryn
    Li, Georgia
    Han, Ling
    Jia, Catherine
    Wang, Lulu
    Chen, Guang
    Subramanian, G. Mani
    Myers, Robert P.
    Djedjos, C. Stephen
    Kohli, Anita
    Bzowej, Natalie
    Younes, Ziad
    Sarin, Shiv
    Shiffman, Mitchell L.
    Harrison, Stephen A.
    Afdhal, Nezam H.
    Goodman, Zachary
    Younossi, Zobair M.
    [J]. HEPATOLOGY, 2019, 70 (05) : 1521 - 1530
  • [8] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [9] Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
    Avgerinos, Ioannis
    Michailidis, Theodoros
    Liakos, Aris
    Karagiannis, Thomas
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03) : 335 - 345
  • [10] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Belfort, Renata
    Harrison, Stephen A.
    Brown, Kenneth
    Darland, Celia
    Finch, Joan
    Hardies, Jean
    Balas, Bogdan
    Gastaldelli, Amalia
    Tio, Fermin
    Pulcini, Joseph
    Berria, Rachele
    Ma, Jennie Z.
    Dwivedi, Sunil
    Havranek, Russell
    Fincke, Chris
    DeFronzo, Ralph
    Bannayan, George A.
    Schenker, Steven
    Cusi, Kenneth
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2297 - 2307